US EditionPublished • loading... • Updated
ErVimmune Raises 17m Euros in Funding to Develop Cancer Vaccine
Summary by pharmatimes.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
French biotech ErVimmune raises €17M to advance off-the-shelf cancer vaccine targeting HERVs - European Biotechnology Magazine
The French preclinical-stage biotech ErVimmune closed a €17 million series A round to bring its lead candidate cancer vaccine into the clinic. The post French biotech ErVimmune raises €17M to advance off-the-shelf cancer vaccine targeting HERVs appeared first on European Biotechnology Magazine.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
